Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2012

View Archived Issues

EE-TP shows promise for the treatment of MNGIE

New DNA supercoiling inhibitors for bacterial infections presented by Biota

Kalidex conducts phase I study of novel fluoroquinolone antibiotic

Teijin Pharma gains rights to investigational bronchial asthma drug

ASSURE trial of RVX-208 completes enrollment

Cannabis Science initiates European preclinical program for CS-TATI-1

Prozymex presents novel dipeptidyl peptidase 1 inhibitors

Chinese researchers synthesize new androgen receptor antagonists

Abbott launches Absorb bioresorbable vascular scaffold

Sanofi discloses several new agents for diabetes

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

Array BioPharma and Genentech report novel ERK inhibitors

Forest Laboratories submits NDA for levomilnacipran

Pharming completes phase III Ruconest study

FDA grants priority review status to sNDA for Amitiza

Bristol-Myers Squibb files application in Japan for Taxol for germ cell tumors

FDA acknowledges receipt of NDA resubmission for Eliquis

Pfizer and Acura Pharmaceuticals terminate license agreement

FDA accepts NDA for FF/VI for COPD

EMA recommends approval of ingenol mebutate for actinic keratosis

UCB's phase IIb study of olokizumab meets primary endpoint

Positive results reported from phase Ib trial of ACH-3102

BioMarin to start phase III program for PEG-PAL in 2013

Merck & Co. returns vernakalant rights

FDA approves Bayer's Stivarga for treatment of metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...